Drugs / Fluorine F 18 rhPSMA-7.3
Fluorine F 18 rhPSMA-7.3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04978675 | Aug 2021 → Jun 2024 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorine F 18 rhPSMA-7.3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04978675 ↗ |
| Modality | Diagnostic / imaging agent | “rhPSMA-7.3 is a radioactive tracer agent that when used with PET/MRI imaging may help diagnose” NCT04978675 ↗ |
| Route | Intravenous | “Patients receive F-18 rhPSMA-7.3 intravenously (IV)” NCT04978675 ↗ |